Faron updated the status of investigator-initiated bexmarilimab studies
Summary
- Faron updated its investigator-initiated trials for bexmarilimab, highlighting changes in the BLAZE trial to use nivolumab, regulatory approval for the BEXAR trial, and the discontinuation of the bexmarilimab cohort in the FINPROVE trial.
- The BLAZE trial now evaluates bexmarilimab with nivolumab in lung cancer or melanoma patients resistant to prior anti-PD-1 therapies, with recruitment preparations underway.
- The BEXAR trial, targeting soft tissue sarcoma, has received necessary approvals and is moving towards patient recruitment.
- The FINPROVE trial's bexmarilimab cohort was halted, while blood cancer studies like BEAM-X and City of Hope continue progressing towards regulatory submissions.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 7/14/2026 at 7:57 am EEST.
On Monday, Faron provided an update on its investigator-initiated trials (IIT) portfolio evaluating bexmarilimab. Key updates were that the combination treatment in the BLAZE trial was changed to nivolumab, the BEXAR trial received regulatory approval, and the bexmarilimab cohort in the FINPROVE trial was shut down. IITs offer new potential indications for bexmarilimab and support the drug candidate’s long-term value. However, from Faron’s investment perspective, they are secondary to the company’s own BEXERA trial, which focuses on blood cancers.
Progress in solid tumor research
In the BLAZE trial, bexmarilimab is being evaluated in combination with the approved anti-PD-1 inhibitor nivolumab in patients with lung cancer or melanoma who have developed resistance to prior anti-PD-1-based therapy. We believe selecting nivolumab as the combination drug is scientifically valid because its efficacy and safety are well-known, which will make it easier to verify the additional benefits provided by bexmarilimab. The study has received the necessary approvals and is progressing towards recruiting the first patient. The BEXAR trial, which focuses on soft tissue sarcoma, has also received regulatory and ethical approvals and is advancing towards patient recruitment.
FINPROVE tests discontinued, blood cancer studies advance
The bexmarilimab cohort in the FINPROVE study being conducted in Finland will not proceed following Fimea’s review, as the platform trial is designed primarily for marketed therapies. Meanwhile, the BEAM-X and City of Hope trials, which focus on blood cancers (AML and MDS), are progressing as planned toward regulatory submissions.
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read more on company pageKey Estimate Figures11/03
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| growth-% | |||
| EBIT (adj.) | -19.0 | -19.0 | -25.0 |
| EBIT-% (adj.) | -474,000.0 % | -475,000.0 % | -625,000.0 % |
| EPS (adj.) | -0.23 | -0.10 | -0.11 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
